Project Grant R43AR086700
Award Date 9/1/26
Completion Date 8/31/28
Dollars Obligated $322K
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Philadelphia, PA 19104, USA
Similar Awards
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded The Regents of the University of California, San Francisco $347,760 on September 1, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The recipient will conduct computational discovery of precision therapeutics for hidradenitis suppurativa, a chronic systemic inflammatory skin disorder. Work comprises three aims: identifying immunologic signatures and pathways in HS...
- The National Institutes of Health National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded Vanderbilt University Medical Center $409,063 on May 15, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to model hidradenitis suppurativa and link genetic susceptibility loci to disease pathogenesis. The project will use mouse molecular genetics, lentiviral delivery, human keratinocyte bioassays, and RNA sequencing to test whether...
- The National Institute of Allergy and Infectious Diseases awarded The Johns Hopkins University $271,574 on November 3, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research on gamma secretase dysregulation in acquired hidradenitis suppurativa. The project, titled "Dysregulation of Gamma Secretase in Common Acquired Hidradenitis Suppurativa" (F30AI191436), investigates the molecular mechanisms underlying hidradenitis suppurativa, a chronic...
- Federal Grant Award Summary Pennsylvania State University, doing business as Penn State Milton S. Hershey Medical Center, received a $366,053 Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), effective August 1, 2025, through June 30, 2027. This award supports fundamental biomedical research investigating the role of non-classical Type I interferons in...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded the Hospital for Special Surgery Fund, Inc. (doing business as HSS Foundation) $473,752 on September 16, 2025, for research developing a circulating cell-free tumor DNA (ctDNA) biomarker to assess immunosuppressive drug safety in patients with immune checkpoint inhibitor-associated inflammatory arthritis (ICI-IA), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The research...
- The National Institutes of Health National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded Alleviate Solutions Inc. $313,012 on September 15, 2025, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to refine a novel at-home kit for contact dermatitis testing and diagnosis. The project delivers a telediagnostic platform combining a skin patch kit, patient and provider mobile applications, and cloud infrastructure. The system uses artificial...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded the University of Connecticut Health Center $658,289 on June 5, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to develop a minimally invasive periarticular injection therapy for managing knee osteoarthritis pain. The project will engineer a combination treatment comprising local anesthetics and a pain modulator delivered via periarticular injection—rather than...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded $314,363 to WNT Scientific LLC on September 16, 2025, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The recipient is developing an intraarticular injectable formulation, StemJel, that encapsulates sclerostin, a Wnt signal inhibitor intended to serve as a disease-modifying osteoarthritis drug (DMOAD) that arrests OA progression and regenerates damaged articular cartilage. The...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded The Johns Hopkins University $569,402 on July 2, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to investigate clinical heterogeneity in immune checkpoint inhibitor-induced inflammatory arthritis. The recipient will conduct prospective clinical studies leveraging the RADIOS (Rheumatology Adverse Events due to Immunotherapy Observational Study) cohort, a multicenter USA...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded The Hospital For Special Surgery Fund, Inc. (HSS Foundation) $129,330 on June 15, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to support Dr. Jannat-Khah's K01 career development study investigating immune checkpoint inhibitor (ICI) treatment outcomes in patients with rheumatoid arthritis and melanoma using real-world data. The award funds research exploring the effect...